Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

Journal of Hepatology

Volumn 68, Issue 6, 2018, Pages 1129-1136

  Papatheodoridis, George V ^a   Sypsa, Vana ^a   Dalekos, George ^b   Yurdaydin, Cihan ^c   van Boemmel, Florian ^d   Buti, Maria ^e   Goulis, John ^f   Calleja, Jose Luis ^g   Chi, Heng ^h   Manolakopoulos, Spilios ^a   Loglio, Alessandro ⁱ   Siakavellas, Spyros ^a   Gatselis, Nikolaos ^b   Keskın, Onur ^c   Lehretz, Maria ^d   Savvidou, Savvoula ^f   de la Revilla, Juan ^g   Hansen, Bettina E ^h   Kourikou, Anastasia ^a   Vlachogiannakos, Ioannis ^a   Galanis, Kostantinos ^b   Idilman, Ramazan ^c   Colombo, Massimo ^j   Esteban, Rafael ^e   Janssen, Harry L A ^h,k   Berg, Thomas ^d   Lampertico, Pietro ⁱ   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

Antiviral therapy; Cirrhosis; Hepatitis B; Hepatocellular carcinoma; Liver transplantation

Indexed keywords

ENTECAVIR; PEGINTERFERON ALPHA; TENOFOVIR; ANTIVIRUS AGENT; GUANINE;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; CHRONIC HEPATITIS B; COHORT ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; PLATELET COUNT; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION; AGED; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; KAPLAN MEIER METHOD; LIVER TUMOR; MULTICENTER STUDY;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TENOFOVIR;

EID: 85042941492     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.01.031     Document Type: Article

References (35)

1. Lampertico, P., Maini, M., Papatheodoridis, G., Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol 63 (2015), 1238–1253.
2. Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 18 (2011), 1–16.
3. Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
4. Hadziyannis, S.J., Papatheodoridis, G.V., Hepatitis Be antigen negative chronic hepatitis B – natural history and treatment. Semin Liver Dis 26 (2006), 130–141.
5. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67 (2017), 370–398.
6. Fattovich, G., Bortolotti, F., Donato, F., Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008), 335–352.
7. Papatheodoridis, G.V., Manesis, E., Hadziyannis, S.J., The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001), 306–313.
8. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
9. Papatheodoridis, G.V., Manolakopoulos, S., Dusheiko, G., Archimandritis, A.J., Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 8 (2008), 167–178.
10. Papatheodoridis, G.V., Dalekos, G.N., Yurdaydin, C., Buti, M., Goulis, J., Arends, P., et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 62 (2015), 363–370.
11. Papatheodoridis, G.V., Chan, H.L., Hansen, B.E., Janssen, H.L., Lampertico, P., Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 62 (2015), 956–967.
12. Vlachogiannakos, J., Papatheodoridis, G., Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 19 (2013), 8822–8830.
13. Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 (2013), 98–107.
14. Wong, G.L., Chan, H.L., Chan, H.Y., Tse, P.C., Tse, Y.K., Mak, C.W., et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 144 (2013), 933–944.
15. Papatheodoridis, G.V., Manolakopoulos, S., Touloumi, G., Nikolopoulou, G., Raptopoulou-Gigi, M., Gogos, C., et al. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat 22 (2015), 120–127.
16. European Association for the Study of the Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
17. Rodger, A.J., Lodwick, R., Schechter, M., Deeks, S., Amin, J., Gilson, R., et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27 (2013), 973–979.
18. Klein, M.B., Rollet-Kurhajec, K.C., Moodie, E.E., Yaphe, S., Tyndall, M., Walmsley, S., et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). AIDS 28 (2014), 1957–1965.
19. Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 64 (2016), 1217–1223.
20. Breslow, N.E., Day, N.E., Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. 1987, International Agency for Research on Cancer, 82, Lyon, France, 1–406.
21. Walter, S.R., Thein, H.H., Amin, J., Gidding, H.F., Ward, K., Law, M.G., et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. J Hepatol 54 (2011), 879–886.
22. Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004), 1521–1531.
23. Lim, Y.S., Han, S., Heo, N.Y., Shim, J.H., Lee, H.C., Suh, D.J., Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs. lamivudine. Gastroenterology 147 (2014), 152–161.
24. Wong, G.L., Chan, H.L., Mak, C.W., Lee, S.K., Ip, Z.M., Lam, A.T., et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58 (2013), 1537–1547.
25. Yuen, M.F., Seto, W.K., Chow, D.H., Tsui, K., Wong, D.K., Ngai, V.W., et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 12 (2007), 1295–1303.
26. Papatheodoridis, G.V., Dimou, E., Dimakopoulos, K., Manolakopoulos, S., Rapti, I., Kitis, G., et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42 (2005), 121–129.
27. Trinchet, J.C., Bourcier, M., Chaffaut, C., Ait Ahmed, M., Allarn, S., Marcellin, P., et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
28. Montuclard, C., Hamza, S., Rollot, F., Evrard, P., Faivre, J., Hillon, P., et al. Causes of death in people with chronic HBV infection: A population-based cohort study. J Hepatol 62 (2015), 1265–1271.
29. Duberg, A.-S., Torner, A., DaviOsdottir, L., Aleman, S., Blaxhult, A., Svensson, A., et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 15 (2008), 538–550.
30. Duffell, E.F., Hedrich, D., Mardh, O., Mozalevskis, A., Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions. Euro Surveill, 22, 2017, 10.2807/1560-7917.
31. Bertuccio, P., Turati, F., Carioli, G., Rodriguez, T., La Vecchia, C., Malvezzi, M., et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67 (2017), 302–309.
32. Chang, T.T., Liaw, Y.F., Wu, S.S., Schiff, E., Han, K.H., Lai, C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52 (2010), 886–893.
33. Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
34. Papatheodoridis, G., Idilman, R., Dalekos, G., Buti, M., Chi, H., Van Boemmel, F., et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir therapy in Caucasians with chronic hepatitis B. Hepatology 66 (2017), 1444–1453.
35. Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 64 (2016), 800–806.